CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published ahead of print on January 16, 2008
Clinical Journal of the American Society of Nephrology
© 2008 American Society of Nephrology
doi: 10.2215/CJN.03820907
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.03820907v1
3/2/407    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paniagua, R.
Right arrow Articles by Horl, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paniagua, R.
Right arrow Articles by Horl, W. H.

Received September 12, 2007
Accepted on November 26, 2007

ORIGINAL ARTICLES

Predictive Value of Brain Natriuretic Peptides in Patients on Peritoneal Dialysis: Results from the ADEMEX Trial

Ramon Paniagua *, Dante Amato *, Salim Mujais {dagger}1, Edward Vonesh {ddagger}, Alfonso Ramos {sect}, Ricardo Correa-Rotter , and Walter H. Horl

For the Mexican Nephrology Collaborative Study Group, *Unidad de Investigacioñ Médica en Enfermedades Nefrolìicas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico; {dagger}Astellas Pharma US, Deerfield, Illinois; {ddagger}Northwestern University, Evanston, Illinois; {sect}Instituto Mexicano del Seguro Social, Hermosillo, Mexico; ||Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Mexico; and ¶Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria


1 To whom correspondence should be addressed. E-mail: salim.mujais{at}gmail.com.


  Abstract

Background and objectives: Natriuretic peptides have been suggested to be of value in risk stratification in dialysis patients. Data in patients on peritoneal dialysis remain limited.

Design, setting, participants, & measurements: Patients of the ADEMEX trial (ADEquacy of peritoneal dialysis in MEXico) were randomized to a control group [standard 4 x 2L continuous ambulatory peritoneal dialysis (CAPD); n = 484] and an intervention group (CAPD with a target creatinine clearance ≥60L/wk/1.73 m2; n = 481). Natriuretic peptides were measured at baseline and correlated with other parameters as well as evaluated for effects on patient outcomes.

Results: Control group and intervention group were comparable at baseline with respect to all measured parameters. Baseline values of natriuretic peptides were elevated and correlated significantly with levels of residual renal function but not with body size or diabetes. Baseline values of N-terminal fragment of B-type natriuretic peptide (NT-proBNP) but not proANP(1–30), proANP(31–67), or proANP(1–98) were independently highly predictive of overall survival and cardiovascular mortality. Volume removal was also significantly correlated with patient survival.

Conclusions: NT-proBNP have a significant predictive value for survival of CAPD patients and may be of value in guiding risk stratification and potentially targeted therapeutic interventions.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American Society of Nephrology.